Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)

France flag France · Delayed Price · Currency is EUR
0.3700
-0.0370 (-9.09%)
Last updated: Jun 3, 2026, 2:27 PM CET
Market Cap7.75M +18.5%
Revenue (ttm)1.81M +10.9%
Net Income5.48M
EPS0.30
Shares Out 19.04M
PE Ratio1.36
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume38,109
Open0.4100
Previous Close0.4070
Day's Range0.3690 - 0.4100
52-Week Range0.2800 - 0.9200
Beta-0.33
Analystsn/a
Price Targetn/a
Earnings DateJul 31, 2026

About EPA:ALOPM

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 14
Stock Exchange Euronext Paris
Ticker Symbol ALOPM
Full Company Profile

Financial Performance

Financial Statements